Study: Erbitux extends survival in head, neck cancer patients

06/3/2007 | CNNMoney/Fortune

The drug from biotech ImClone Systems, Bristol-Myers Squibb and Merck KGaA extended survival for advanced head and neck cancer patients by an average of 2.7 months. The study followed 222 patients who took Erbitux with chemotherapy and 220 on chemotherapy alone and found Erbitux patients survived an average 10.1 months versus 7.4 months otherwise.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL